Amlodipine, felodipine, nifedipine, lercanidipine, diltiazem, verapamil, Amlodipine/diltiazem, and felodipine/verapamil
CCB-users more likely to suffer from moderate-severe LUTS than non-CCB-users () High significant association of Amlodipine/nifedipine (9.8; 95% CI: 3.98–24.3, ) and diltiazem/verapamil (8.2; 95% CI: 1.93–34.9, ) with severe LUTS Significantly higher odds of moderate-severe LUTS with CCB (amlodipine/nifedipine, and diltiazem/verapamil 37.5; 95% CI: 8.6–163.9, )
CCB-users had statistically significantly higher scores of Benign prostate hyperplasia impact index () and IPSS-QOL question ().
Monotherapy of CCB is associated with higher prevalence of nocturia (OR 2.65; 95% CI: 1.04–6.74, ) and voiding symptoms (OR 2.59; 95% CI: 1.24–11.87, ) in young females (<55 years); no associations of CCB (monotherapy and CCB use with other AHT) with LUTS in males